Sequoia Financial Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 148.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 268,283 shares of the biopharmaceutical company’s stock after acquiring an additional 160,386 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Pfizer were worth $10,946,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Lam Group Inc. purchased a new position in shares of Pfizer during the 4th quarter valued at about $25,000. Worth Asset Management LLC purchased a new position in shares of Pfizer during the 1st quarter valued at about $29,000. My Personal CFO LLC purchased a new position in shares of Pfizer during the 4th quarter valued at about $32,000. Mendota Financial Group LLC purchased a new position in Pfizer in the 4th quarter worth approximately $33,000. Finally, Freedom Wealth Alliance LLC purchased a new position in Pfizer in the 4th quarter worth approximately $35,000. Institutional investors own 67.80% of the company’s stock.
Pfizer Trading Down 0.3 %
NYSE PFE opened at $35.53 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31. Pfizer Inc. has a twelve month low of $35.35 and a twelve month high of $54.93. The firm has a market capitalization of $200.58 billion, a PE ratio of 6.99, a P/E/G ratio of 1.18 and a beta of 0.61. The stock’s 50 day moving average is $38.03 and its 200 day moving average is $41.50.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 4.62%. The ex-dividend date is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is 32.28%.
Insiders Place Their Bets
In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction on Monday, May 8th. The shares were acquired at an average cost of $38.58 per share, with a total value of $38,580.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $231,480. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on PFE. Morgan Stanley decreased their price target on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, April 10th. Bank of America decreased their price target on Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research note on Friday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Pfizer in a research note on Wednesday, May 17th. UBS Group decreased their price target on Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Finally, StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $46.67.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
